We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > risankizumab

News List

AbbVie seeks EMA approval for risankizumab (Skyrizi) to treat moderate to severe Crohn’s disease Pharmaceutical-Business-Review
December 02, 2021
AbbVie has sought approval from the European Medicines Agency (EMA) for risankizumab (Skyrizi, 600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), to treat patients who are 16 years and above suffering with moderate to...
Risankizumab induces deep remissions in Crohn’s disease trial europeanpharmaceuticalreview
June 04, 2021
Phase III trial data shows more than half of patients with moderate to severe Crohn’s disease treated with risankizumab (Skyrizi®) 360mg achieved clinical remission in a year.
Risankizumab trials show higher clinical remission in patients with Crohn’s disease europeanpharmaceuticalreview
January 12, 2021
Two Phase III trials have shown that two doses of risankizumab met the primary endpoints in patients with Crohn’s disease.
NICE recommends risankizumab to treat severe psoriasis europeanpharmaceuticalreview
July 15, 2019
NICE has issued a recommendation for risankizumab to treat patients with severe plaque psoriasis.
AbbVie files risankizumab in the US pharmatimes
April 28, 2018
AbbVie has filed risankizumab in the US seeking approval for its use to treat moderate-to-severe plaque psoriasis.